MYCOTOPIA THERAPIES INC - TPIA STOCK NEWS

Mycotopia Therapies Inc. (OTC: TPIA) has acquired certain assets of Philon Labs, LLC, including patents for AI robotics-based home health products. The acquisition marks the company's transition to a growth-oriented entity focused on AI-enhanced products. The patents relate to the 'Milkyway' smart fridge for breast milk storage bags and the 'Phill Robot' massage robot, both utilizing advanced AI technology. Mycotopia Therapies will rebrand as AiBotics and change its trading symbol to ABIT. The acquisition involves issuing new class of Preferred Stock valued at $2,000,000 convertible into shares of the Common Stock of Mycotopia.

Ei.Ventures and Mycotopia Therapies (OTC: TPIA) announced the termination of their merger agreement with PSLY.com, Inc., which was initially established on May 17, 2022. The decision to end the merger, effective February 16, 2023, stems from unfavorable market conditions and the belief that this timing does not optimize shareholder value. Following this, PSLY.com will withdraw its SEC filing and discontinue its NASDAQ listing application. Both CEOs expressed disappointment but acknowledged the necessity of this decision in the current economic landscape.

Mycotopia Therapies Inc. (TPIA) announced a merger with Ei.Ventures Inc., forming PSLY.com and targeting a NASDAQ listing. The merger values Ei at approximately $360 million and Mycotopia at over $23 million. Upon completion, PSLY.com will have a market value of $383 million. The companies aim to leverage their combined resources in legal psilocybin markets, enhancing product offerings like Odyssey Elixir and Psilly patches. The transaction is expected to close around July 30, 2022.

Mycotopia Therapies (TPIA) and Ei.Ventures have announced strategic investments to advance their business plan, focusing on plant-based psychedelic therapies. The combined entity, renamed PSLY.COM, aims to develop botanical psychedelic APIs and therapeutics, differentiating itself from competitors focused on synthetic drugs. Key investments include $1.111 million in Avicanna and Odyssey Elixir, supporting their growth in the psychedelic market. As they approach a $360 million public transaction, both companies emphasize their commitment to mental wellness through natural therapies and Web 3.0 integration.

Mycotopia Therapies Inc. (OTC Pink: TPIA) has announced a partnership with PsychedelicsEUROPE to enhance psychedelic research and develop regulatory frameworks for medicinal use in Europe. The collaboration is driven by the increasing acceptance of psychedelic medicine for treating mental health issues, particularly depression. CEO Ben Kaplan highlighted the potential for transformative patient treatments and ongoing acquisition efforts for Ei.Ventures to expand their psychedelic assets.

Mycotopia Therapies (OTC Pink: TPIA) is advancing plans to enter the $13 billion medicinal mushroom market through the formation of PSLY.COM with Ei.Ventures. The company will utilize HAVN Life Sciences's functional mushrooms in its MANA product line, aimed at consumers. Mycotopia will also acquire a $2.2 million virtual estate in The Sandbox, bolstering its metaverse presence. Following the acquisition of Ei.Ventures, PSLY.COM intends to pursue a NASDAQ listing and focus on therapeutic and non-psychoactive mushroom nutraceuticals, targeting significant growth in the mushroom and telepsychiatry markets.

Mycotopia Therapies (OTC Pink: TPIA) has expanded its supply agreement with Havn Life Sciences to include functional mushrooms, enhancing its distribution capabilities for naturally-derived psilocybin and OTC health products in Jamaica. The Jamaican Ministry of Health is involved in the registration of these products. Mycotopia also plans to combine its resources with Ei.Ventures for developing psilocybin therapies, with the goal of addressing global mental healthcare needs. The collaboration is expected to alleviate supply chain issues and facilitate revenue generation.

Mycotopia Therapies (TPIA) announced the acquisition of a 12x12 estate in The Sandbox, valuing $2.2M, marking it as the third largest land sale in the Metaverse. This digital land, named PSLY.COM, reflects the synergy between Mycotopia and Ei.Ventures, aiming to blend psychedelic therapy with blockchain technology. Ei.Ventures now owns a total of 144 Sandbox plots. CEO Ben Kaplan cites a booming market, with total sales in The Sandbox reaching $211 million, and anticipates beneficial returns for shareholders from this strategic investment.

Mycotopia Therapies (OTC Pink: TPIA) announced a letter of intent to acquire Ei.Ventures, a pioneer in botanical psilocybin. The acquisition aims to combine resources to develop regulatory-approved therapeutic options and nutritional supplements targeting global mental health needs. The transaction is expected to finalize by Q1 2022, with intentions to rebrand as PSLY.COM. Key products include Psilly, a botanical psilocybin formulation in pre-clinical stages, leveraging the potential 'Entourage Effect' for therapeutic benefits.